Phaseline

Targets › ENO1

ENO1 (Alpha-enolase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2027.

Enolase that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction in gluconeogenesis. Also involved in various processes such as growth control, hypoxia tolerance and allergic responses. (UniProt, P06733)

Open in Phaseline: the race on ENO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HuniLife BiotechnologyHuL001
Anti-ENO1 monoclonal antibody
ENO1Phase 1Multiple Myeloma RefractoryNov 2027

Conditions

Multiple Myeloma Refractory (1)

Modalities

small molecule (1)

Companies

HuniLife Biotechnology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.